Open Access

[Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

  • Authors:
    • Yasuyoshi Miyata
    • Kyohei Araki
    • Kojiro Ohba
    • Tomhiro Mastuo
    • Yuichiro Nakamura
    • Tsutomu Yuno
    • Yuta Mukai
    • Asato Otsubo
    • Kensuke Mitsunari
    • Yasushi Mochizuki
    • Hideki Sakai
  • View Affiliations

  • Published online on: September 25, 2020     https://doi.org/10.3892/mco.2020.2148
  • Article Number: 78
  • Copyright : © Miyata et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

Related Articles

Journal Cover

December-2020
Volume 13 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Miyata Y, Araki K, Ohba K, Mastuo T, Nakamura Y, Yuno T, Mukai Y, Otsubo A, Mitsunari K, Mochizuki Y, Mochizuki Y, et al: [Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial. Mol Clin Oncol 13: 78, 2020
APA
Miyata, Y., Araki, K., Ohba, K., Mastuo, T., Nakamura, Y., Yuno, T. ... Sakai, H. (2020). [Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial. Molecular and Clinical Oncology, 13, 78. https://doi.org/10.3892/mco.2020.2148
MLA
Miyata, Y., Araki, K., Ohba, K., Mastuo, T., Nakamura, Y., Yuno, T., Mukai, Y., Otsubo, A., Mitsunari, K., Mochizuki, Y., Sakai, H."[Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial". Molecular and Clinical Oncology 13.6 (2020): 78.
Chicago
Miyata, Y., Araki, K., Ohba, K., Mastuo, T., Nakamura, Y., Yuno, T., Mukai, Y., Otsubo, A., Mitsunari, K., Mochizuki, Y., Sakai, H."[Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial". Molecular and Clinical Oncology 13, no. 6 (2020): 78. https://doi.org/10.3892/mco.2020.2148